{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T01:02:48Z","timestamp":1759798968960,"version":"build-2065373602"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,6]]},"DOI":"10.7759\/cureus.93950","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:25:39Z","timestamp":1759775139000},"source":"Crossref","is-referenced-by-count":0,"title":["Adenosine A3 Receptor and Its Potential Role in Cancer Treatment: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Joseph V","family":"Pergolizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo Ann K","family":"LeQuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark H","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/1061186X.2015.1058803","article-title":"Adenosine-associated delivery systems","volume":"23","author":"Kazemzadeh-Narbat M","year":"2015","unstructured":"Kazemzadeh-Narbat M, Annabi N, Tamayol A, Oklu R, Ghanem A, Khademhosseini A. Adenosine-associated delivery systems. J Drug Target. 2015, 23:580-96. 10.3109\/1061186X.2015.1058803","journal-title":"J Drug Target"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1039\/d5ra02235e","article-title":"Therapeutic potential of adenosine receptor modulators in cancer treatment","volume":"15","author":"Maity P","year":"2025","unstructured":"Maity P, Ganguly S, Deb PK. Therapeutic potential of adenosine receptor modulators in cancer treatment. RSC Adv. 2025, 15:20418-45. 10.1039\/d5ra02235e","journal-title":"RSC Adv"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-2952(00)00570-0","article-title":"Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells","volume":"61","author":"Fredholm BB","year":"2001","unstructured":"Fredholm BB, Irenius E, Kull B, Schulte G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol. 2001, 61:443-8. 10.1016\/s0006-2952(00)00570-0","journal-title":"Biochem Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.003285","article-title":"International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update","volume":"63","author":"Fredholm BB","year":"2011","unstructured":"Fredholm BB, IJzerman AP, Jacobson KA, Linden J, M\u00fcller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev. 2011, 63:1-34. 10.1124\/pr.110.003285","journal-title":"Pharmacol Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-021-00766-y","article-title":"Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases","volume":"28","author":"Chang CP","year":"2021","unstructured":"Chang CP, Wu KC, Lin CY, Chern Y. Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases. J Biomed Sci. 2021, 28:70. 10.1186\/s12929-021-00766-y","journal-title":"J Biomed Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3613","article-title":"Immunity, inflammation and cancer: a leading role for adenosine","volume":"13","author":"Antonioli L","year":"2013","unstructured":"Antonioli L, Blandizzi C, Pacher P, Hask\u00f3 G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013, 13:842-57. 10.1038\/nrc3613","journal-title":"Nat Rev Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2014.02.009","article-title":"Adenosine: physiology, pharmacology, and clinical applications","volume":"7","author":"Layland J","year":"2014","unstructured":"Layland J, Carrick D, Lee M, Oldroyd K, Berry C. Adenosine: physiology, pharmacology, and clinical applications. JACC Cardiovasc Interv. 2014, 7:581-91. 10.1016\/j.jcin.2014.02.009","journal-title":"JACC Cardiovasc Interv"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202200064","article-title":"The complex roles of adenosine triphosphate in bioenergetics","volume":"23","author":"Fontecilla-Camps JC","year":"2022","unstructured":"Fontecilla-Camps JC. The complex roles of adenosine triphosphate in bioenergetics. Chembiochem. 2022, 23:e202200064. 10.1002\/cbic.202200064","journal-title":"Chembiochem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2015.03.009","article-title":"Neurohormetic phytochemicals: an evolutionary-bioenergetic perspective","volume":"89","author":"Murugaiyah V","year":"2015","unstructured":"Murugaiyah V, Mattson MP. Neurohormetic phytochemicals: an evolutionary-bioenergetic perspective. Neurochem Int. 2015, 89:271-80. 10.1016\/j.neuint.2015.03.009","journal-title":"Neurochem Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-013-1101-6","article-title":"Adenosine--a physiological or pathophysiological agent?","volume":"92","author":"Fredholm BB","year":"2014","unstructured":"Fredholm BB. Adenosine--a physiological or pathophysiological agent?. J Mol Med (Berl). 2014, 92:201-6. 10.1007\/s00109-013-1101-6","journal-title":"J Mol Med (Berl)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard B","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020, 17:611-29. 10.1038\/s41571-020-0382-2","journal-title":"Nat Rev Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22030449","article-title":"Structual probing and molecular modeling of the A3 adenosine receptor: a focus on agonist binding","volume":"22","author":"Ciancetta A","year":"2017","unstructured":"Ciancetta A, Jacobson KA. Structual probing and molecular modeling of the A3 adenosine receptor: a focus on agonist binding. Molecules. 2017, 22:449. 10.3390\/molecules22030449","journal-title":"Molecules"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(94)90011-6","article-title":"Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions","volume":"15","author":"Linden J","year":"1994","unstructured":"Linden J. Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci. 1994, 15:298-306. 10.1016\/0165-6147(94)90011-6","journal-title":"Trends Pharmacol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200308260-00021","article-title":"Adenosine A3 receptors are located in neurons of the rat hippocampus","volume":"14","author":"Lopes LV","year":"2003","unstructured":"Lopes LV, Rebola N, Pinheiro PC, Richardson PJ, Oliveira CR, Cunha RA. Adenosine A3 receptors are located in neurons of the rat hippocampus. Neuroreport. 2003, 14:1645-8. 10.1097\/00001756-200308260-00021","journal-title":"Neuroreport"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111886","article-title":"Conjugable A(3) adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes","volume":"186","author":"Federico S","year":"2020","unstructured":"Federico S, Margiotta E, Moro S, Kozma E, Gao ZG, Jacobson KA, Spalluto G. Conjugable A(3) adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes. Eur J Med Chem. 2020, 186:111886. 10.1016\/j.ejmech.2019.111886","journal-title":"Eur J Med Chem"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102603","article-title":"Role of mast cell-derived adenosine in cancer","volume":"20","author":"Gorzalczany Y","year":"2019","unstructured":"Gorzalczany Y, Sagi-Eisenberg R. Role of mast cell-derived adenosine in cancer. Int J Mol Sci. 2019, 20:2603. 10.3390\/ijms20102603","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2019.1630380","article-title":"Targeting A3 and A2A adenosine receptors in the fight against cancer","volume":"23","author":"Merighi S","year":"2019","unstructured":"Merighi S, Battistello E, Giacomelli L, Varani K, Vincenzi F, Borea PA, Gessi S. Targeting A3 and A2A adenosine receptors in the fight against cancer. Expert Opin Ther Targets. 2019, 23:669-78. 10.1080\/14728222.2019.1630380","journal-title":"Expert Opin Ther Targets"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108871","article-title":"Targeting immunosuppressive adenosine signaling: a review of potential immunotherapy combination strategies","volume":"24","author":"Zahavi D","year":"2023","unstructured":"Zahavi D, Hodge JW. Targeting immunosuppressive adenosine signaling: a review of potential immunotherapy combination strategies. Int J Mol Sci. 2023, 24:8871. 10.3390\/ijms24108871","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-023-09925-2","article-title":"Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects","volume":"19","author":"Fishman P","year":"2023","unstructured":"Fishman P, Stemmer SM, Bareket-Samish A, Silverman MH, Kerns WD. Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects. Purinergic Signal. 2023, 19:513-22. 10.1007\/s11302-023-09925-2","journal-title":"Purinergic Signal"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008922","article-title":"Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model","volume":"5","author":"Yang Z","year":"2010","unstructured":"Yang Z, Zhang B, Li D, Lv M, Huang C, Shen GX, Huang B. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One. 2010, 5:e8922. 10.1371\/journal.pone.0008922","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00134","article-title":"Mast cell adenosine receptors function: a focus on the A3 adenosine receptor and inflammation","volume":"3","author":"Rudich N","year":"2012","unstructured":"Rudich N, Ravid K, Sagi-Eisenberg R. Mast cell adenosine receptors function: a focus on the A3 adenosine receptor and inflammation. Front Immunol. 2012, 3:134. 10.3389\/fimmu.2012.00134","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2018.02.019","article-title":"Stimulation of the adenosine A3 receptor, not the A1 or A2 receptors, promote neurite outgrowth of retinal ganglion cells","volume":"170","author":"Nakashima KI","year":"2018","unstructured":"Nakashima KI, Iwao K, Inoue T, et al.. Stimulation of the adenosine A3 receptor, not the A1 or A2 receptors, promote neurite outgrowth of retinal ganglion cells. Exp Eye Res. 2018, 170:160-8. 10.1016\/j.exer.2018.02.019","journal-title":"Exp Eye Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02090-z","article-title":"Cancer biology and molecular genetics of A(3) adenosine receptor","volume":"41","author":"Mazziotta C","year":"2022","unstructured":"Mazziotta C, Rotondo JC, Lanzillotti C, Campione G, Martini F, Tognon M. Cancer biology and molecular genetics of A(3) adenosine receptor. Oncogene. 2022, 41:301-8. 10.1038\/s41388-021-02090-z","journal-title":"Oncogene"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/med.21456","article-title":"A3 adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy","volume":"38","author":"Jacobson KA","year":"2018","unstructured":"Jacobson KA, Merighi S, Varani K, et al.. A3 adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy. Med Res Rev. 2018, 38:1031-72. 10.1002\/med.21456","journal-title":"Med Res Rev"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(17)32856-9","article-title":"Regulation of de novo purine biosynthesis in human lymphoblasts. Coordinate control of proximal (rate-determining) steps and the inosinic acid branch point","volume":"251","author":"Hershfield M","year":"1976","unstructured":"Hershfield M, Seegmiller J. Regulation of de novo purine biosynthesis in human lymphoblasts. Coordinate control of proximal (rate-determining) steps and the inosinic acid branch point. J Biol Chem. 1976, 251:7348-54.","journal-title":"J Biol Chem"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00627","article-title":"Who is who in adenosine transport","volume":"9","author":"Pastor-Anglada M","year":"2018","unstructured":"Pastor-Anglada M, P\u00e9rez-Torras S. Who is who in adenosine transport. Front Pharmacol. 2018, 9:627. 10.3389\/fphar.2018.00627","journal-title":"Front Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000174112.36064.77","article-title":"Control of adenosine transport by hypoxia","volume":"97","author":"G\u00f6rlach A","year":"2005","unstructured":"G\u00f6rlach A. Control of adenosine transport by hypoxia. Circ Res. 2005, 97:1-3. 10.1161\/01.RES.0000174112.36064.77","journal-title":"Circ Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0651","article-title":"The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition","volume":"10","author":"Madi L","year":"2004","unstructured":"Madi L, Ochaion A, Rath-Wolfson L, et al.. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res. 2004, 10:4472-9. 10.1158\/1078-0432.CCR-03-0651","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1134-03","article-title":"Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells","volume":"10","author":"Gessi S","year":"2004","unstructured":"Gessi S, Cattabriga E, Avitabile A, et al.. Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res. 2004, 10:5895-901. 10.1158\/1078-0432.CCR-1134-03","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123837","article-title":"Targeting adenosine receptor signaling in cancer immunotherapy","volume":"19","author":"Sek K","year":"2018","unstructured":"Sek K, M\u00f8lck C, Stewart GD, Kats L, Darcy PK, Beavis PA. Targeting adenosine receptor signaling in cancer immunotherapy. Int J Mol Sci. 2018, 19:3837. 10.3390\/ijms19123837","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.03.026","article-title":"Mast cells are directly activated by contact with cancer cells by a mechanism involving autocrine formation of adenosine and autocrine\/paracrine signaling of the adenosine A3 receptor","volume":"397","author":"Gorzalczany Y","year":"2017","unstructured":"Gorzalczany Y, Akiva E, Klein O, Merimsky O, Sagi-Eisenberg R. Mast cells are directly activated by contact with cancer cells by a mechanism involving autocrine formation of adenosine and autocrine\/paracrine signaling of the adenosine A3 receptor. Cancer Lett. 2017, 397:23-32. 10.1016\/j.canlet.2017.03.026","journal-title":"Cancer Lett"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.10.1601","article-title":"The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis","volume":"16","author":"Bar-Yehuda S","year":"2007","unstructured":"Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs. 2007, 16:1601-13. 10.1517\/13543784.16.10.1601","journal-title":"Expert Opin Investig Drugs"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/etc.4029","article-title":"Environmental doses of perfluorooctanoic acid change the expression of genes in target tissues of common carp","volume":"37","author":"Rotondo JC","year":"2018","unstructured":"Rotondo JC, Giari L, Guerranti C, Tognon M, Castaldelli G, Fano EA, Martini F. Environmental doses of perfluorooctanoic acid change the expression of genes in target tissues of common carp. Environ Toxicol Chem. 2018, 37:942-8. 10.1002\/etc.4029","journal-title":"Environ Toxicol Chem"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce JA","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015, 348:74-80. 10.1126\/science.aaa6204","journal-title":"Science"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2006.03.020","article-title":"Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells","volume":"72","author":"Merighi S","year":"2006","unstructured":"Merighi S, Benini A, Mirandola P, et al.. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol. 2006, 72:19-31. 10.1016\/j.bcp.2006.03.020","journal-title":"Biochem Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.60","article-title":"Cancer metabolism: a therapeutic perspective","volume":"14","author":"Martinez-Outschoorn UE","year":"2017","unstructured":"Martinez-Outschoorn UE, Peiris-Pag\u00e9s M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017, 14:11-31. 10.1038\/nrclinonc.2016.60","journal-title":"Nat Rev Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1298487","article-title":"Editorial: adenosine pathways in cancer immunity and immunotherapy","volume":"14","author":"Fu J","year":"2023","unstructured":"Fu J, Antonioli L, El-Far AH. Editorial: adenosine pathways in cancer immunity and immunotherapy. Front Immunol. 2023, 14:1298487. 10.3389\/fimmu.2023.1298487","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01370-0","article-title":"Implications of HIF-1\u03b1 in the tumorigenesis and progression of pancreatic cancer","volume":"20","author":"Jin X","year":"2020","unstructured":"Jin X, Dai L, Ma Y, Wang J, Liu Z. Implications of HIF-1\u03b1 in the tumorigenesis and progression of pancreatic cancer. Cancer Cell Int. 2020, 20:273. 10.1186\/s12935-020-01370-0","journal-title":"Cancer Cell Int"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1593\/neo.05334","article-title":"A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells","volume":"7","author":"Merighi S","year":"2005","unstructured":"Merighi S, Benini A, Mirandola P, et al.. A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia. 2005, 7:894-903. 10.1593\/neo.05334","journal-title":"Neoplasia"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan D","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011, 144:646-74. 10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.08.018","article-title":"Role of the immunosuppressive microenvironment in immunotherapy","volume":"3","author":"Tormoen GW","year":"2018","unstructured":"Tormoen GW, Crittenden MR, Gough MJ. Role of the immunosuppressive microenvironment in immunotherapy. Adv Radiat Oncol. 2018, 3:520-6. 10.1016\/j.adro.2018.08.018","journal-title":"Adv Radiat Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101304","article-title":"Targeting the adenosine pathway for cancer immunotherapy","volume":"42","author":"Hammami A","year":"2019","unstructured":"Hammami A, Allard D, Allard B, Stagg J. Targeting the adenosine pathway for cancer immunotherapy. Semin Immunol. 2019, 42:101304. 10.1016\/j.smim.2019.101304","journal-title":"Semin Immunol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00155-y","article-title":"Beyond immune checkpoint blockade: emerging immunological strategies","volume":"20","author":"Kubli SP","year":"2021","unstructured":"Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW. Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov. 2021, 20:899-919. 10.1038\/s41573-021-00155-y","journal-title":"Nat Rev Drug Discov"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: the state of the art","volume":"98","author":"Borea PA","year":"2018","unstructured":"Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of adenosine receptors: the state of the art. Physiol Rev. 2018, 98:1591-625. 10.1152\/physrev.00049.2017","journal-title":"Physiol Rev"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.610492","article-title":"Role of the NLRP3 inflammasome: insights into cancer hallmarks","volume":"11","author":"Lin TY","year":"2020","unstructured":"Lin TY, Tsai MC, Tu W, Yeh HC, Wang SC, Huang SP, Li CY. Role of the NLRP3 inflammasome: insights into cancer hallmarks. Front Immunol. 2020, 11:610492. 10.3389\/fimmu.2020.610492","journal-title":"Front Immunol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley N","year":"2019","unstructured":"Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019, 20:3328. 10.3390\/ijms20133328","journal-title":"Int J Mol Sci"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.03.002","article-title":"DAMPs and DAMP-sensing receptors in inflammation and diseases","volume":"57","author":"Ma M","year":"2024","unstructured":"Ma M, Jiang W, Zhou R. DAMPs and DAMP-sensing receptors in inflammation and diseases. Immunity. 2024, 57:752-71. 10.1016\/j.immuni.2024.03.002","journal-title":"Immunity"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2010.12.014","article-title":"Mast cells and inflammation","volume":"1822","author":"Theoharides TC","year":"2012","unstructured":"Theoharides TC, Alysandratos KD, Angelidou A, et al.. Mast cells and inflammation. Biochim Biophys Acta. 2012, 1822:21-33. 10.1016\/j.bbadis.2010.12.014","journal-title":"Biochim Biophys Acta"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2024.10.003","article-title":"A reappraisal of IL-9 in inflammation and cancer","volume":"18","author":"Bick F","year":"2025","unstructured":"Bick F, Blanchetot C, Lambrecht BN, Schuijs MJ. A reappraisal of IL-9 in inflammation and cancer. Mucosal Immunol. 2025, 18:1-15. 10.1016\/j.mucimm.2024.10.003","journal-title":"Mucosal Immunol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2011.06.007","article-title":"The relationship between the neuromodulator adenosine and behavioral symptoms of autism","volume":"500","author":"Masino SA","year":"2011","unstructured":"Masino SA, Kawamura M Jr, Plotkin LM, Svedova J, DiMario FJ Jr, Eigsti IM. The relationship between the neuromodulator adenosine and behavioral symptoms of autism. Neurosci Lett. 2011, 500:1-5. 10.1016\/j.neulet.2011.06.007","journal-title":"Neurosci Lett"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.70024","article-title":"Adenosine A(3) receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro study","volume":"15","author":"Morelli MB","year":"2025","unstructured":"Morelli MB, Spinaci A, Chang C, et al.. Adenosine A(3) receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro study. FEBS Open Bio. 2025, 15:1159-75. 10.1002\/2211-5463.70024","journal-title":"FEBS Open Bio"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0211","article-title":"CF102 for the treatment of hepatocellular carcinoma: a phase I\/II, open-label, dose-escalation study","volume":"18","author":"Stemmer SM","year":"2013","unstructured":"Stemmer SM, Benjaminov O, Medalia G, et al.. CF102 for the treatment of hepatocellular carcinoma: a phase I\/II, open-label, dose-escalation study. Oncologist. 2013, 18:25-6. 10.1634\/theoncologist.2012-0211","journal-title":"Oncologist"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020187","article-title":"Namodenoson in advanced hepatocellular carcinoma and Child-Pugh B cirrhosis: randomized placebo-controlled clinical trial","volume":"13","author":"Stemmer SM","year":"2021","unstructured":"Stemmer SM, Manojlovic NS, Marinca MV, et al.. Namodenoson in advanced hepatocellular carcinoma and Child-Pugh B cirrhosis: randomized placebo-controlled clinical trial. Cancers (Basel). 2021, 13:187. 10.3390\/cancers13020187","journal-title":"Cancers (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/412979-adenosine-a3-receptor-and-its-potential-role-in-cancer-treatment-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:25:40Z","timestamp":1759775140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/412979-adenosine-a3-receptor-and-its-potential-role-in-cancer-treatment-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.93950","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,6]]}}}